Ameliorative potential of coumaric acid and imeglimin against reserpine-induced parkinsonism in rats
DOI:
https://doi.org/10.69857/joapr.v13i6.1815Keywords:
Coumaric acid, imeglimin, α-synuclein expression, oxidative stress, neuroinflammationAbstract
Background: Parkinson’s disease involves dopaminergic degeneration, oxidative stress, and α-synuclein aggregation. Reserpine-induced Parkinsonism mimics these deficits via VMAT-2 inhibition. Coumaric acid and imeglimin possess antioxidant and mitochondrial-protective actions. This study evaluated the individual and combined efficacy of these agents in reducing reserpine-induced behavioural and neurochemical impairments in rats. Methodology: PD was induced in rats by giving reserpine (1 mg/kg, s.c) alternately for three days. Pretreatment with coumaric acid (80 and 100 mg/kg, p.o.), imeglimin (100 & 200 mg/kg, p.o.), and their combination were administered for 5 days. Behavioral assessments (orofacial dyskinesia, H & B test, and rotarod) were performed on day 5, followed by biochemical oxidative stress parameters (CAT, GSH, SOD, and LPO), neurotransmitters (dopamine), and α-synuclein expression with histopathological evaluations. Results: Reserpine-treated rats exhibited pronounced orofacial dyskinesia, reduced motor coordination, dopamine depletion, elevated oxidative stress, and α-synuclein expression. Pretreatment with coumaric acid and imeglimin improved behavioral outcomes, restored antioxidant enzymes, reduced inflammation, and elevated dopamine levels. Combination therapy produced the greatest improvement. Discussion: The combined effects of coumaric acid and imeglimin likely counteract reserpine-induced dopaminergic toxicity through antioxidant enhancement and inhibition of α-synuclein expression. Conclusion: Coumaric acid and imeglimin combination therapy significantly mitigates reserpine-induced Parkinsonism by improving general neuronal integrity and brain function.
Downloads
References
Prajjwal P, Flores Sanga HS, Acharya K, Patel V, Sharma A, Singh R, et al. Parkinson's disease updates: addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment. Ann. Med. Surg. (Lond.), 85(10), 4887–4902 (2023) https://doi.org/10.1097/MS9.0000000000001142
Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK. Role of dopamine in the pathophysiology of Parkinson's disease. Transl. Neurodegener., 12(1), 44–67 (2023) https://doi.org/10.1186/s40035-023-00378-6
Pawar SH, Patil RA, Pawar KV, Paspohe SP, Katti SA, Tayde MA. In silico evaluation of some phenolic acids for their neuroprotective effect. Bull. Environ. Pharmacol. Life Sci., 12(9), 54–8 (2023).
Pidathala S, Liao S, Dai Y, Li X, Long C, Chang C-L, et al. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2. Nature, 623(7989), 1086–92 (2023) https://doi.org/10.1038/s41586-023-06727-9
Alwindi M, Bizanti A. Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions. Heliyon, 9(11), e22413 (2023) https://doi.org/10.1016/j.heliyon.2023.e22413
Bej E, Cesare P, Volpe AR, D’Angelo M, Castelli V. Oxidative stress and neurodegeneration: insights and therapeutic strategies for Parkinson’s disease. Neurol. Int., 16(3), 502–17 (2024) https://doi.org/10.3390/neurolint16030037
Rudrapal M, Khairnar S, Khan MR, Dukhyil A, Ansari KM, Alomary MN, et al. Dietary polyphenols and their role in oxidative stress-induced human diseases: insights into protective effects, antioxidant potentials and mechanisms of action. Phytother. Res., 36(12), 5323–49 (2022) https://doi.org/10.1002/ptr.7601
Aravanan P, Gowrish R, Pramoth GK, Francis UJ, Hasan AIM, Moideen K, et al. The future of medicine: strategic insights into drug repurposing. World J. Biol. Pharm. Health Sci., 20(2), 234–52 (2024) https://doi.org/10.30574/wjbphs.2024.20.2.0845
Hallakou-Bozec S, Vial G, Kergoat M, Bolze S, Bolze F, Fouqueray P, et al. Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes. Metab., 23(3), 664–73 (2021) https://doi.org/10.1111/dom.14277
Sadeghi Nejad Z, Kazemian S, Galedari A, Salmani ME, Reisi P, Sheibani V, et al. Naringenin mitigates reserpine-induced anxiety-like behavior, neurodegeneration, and oxidative stress in male rats. Neurosci. Behav. Physiol., 53, 1–7 (2023) https://doi.org/10.1007/s11055-023-01401-z
Foudah AI, Alqarni MH, Alam A, Devi S, Salkini MA, Alam P, et al. Rutin improves anxiety and reserpine-induced depression in rats. Molecules, 27(21), 7313 (2022) https://doi.org/10.3390/molecules27217313
Hayrapetyan NK, Badalyan IA. Correction by antioxidants of oxidative activity in an experimental model of Parkinson’s disease induced by reserpine: effects of Lycium barbarum (goji berry). Proc. YSU B Chem. Biol. Sci., 57(3), 282–91 (2023) https://doi.org/10.46991/PYSU.B/2023.57.3.282
Chhatrola S, Tirgar P. Evaluating the antiparkinsonian activity of Tamarix gallica extract in a reserpine-induced rat model of Parkinsonism: behavioral and neurochemical assessments. Egypt. J. Neurosurg., 40, 75 (2025) https://doi.org/10.1186/s41984-025-00419-4
Lima AC, Beserra-Filho CA, Cerqueira NJ, Lins KE, Lima LV, Lima FR, et al. Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism. Front. Pharmacol., 16, 1539783 (2025) https://doi.org/10.3389/fphar.2025.1539783
Tharwat EK, Abdelaty AO, Abdelrahman AI, Elsaeed H, El-Feky AS, Ebrahim YM, et al. Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson’s disease induced by reserpine. Metab. Brain Dis., 38, 1513–29 (2023) https://doi.org/10.1007/s11011-023-01189-4
Beserra-Filho CA, Cerqueira NJ, Lins KE, Lima LV, Lima FR, de Souza A, et al. Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism. Front. Pharmacol., 16, 1539783 (2025) https://doi.org/10.3389/fphar.2025.1539783
Syed LAS, Balaji PV, Aravind KR, Thirumaran M, Manibalan V, Rajavel R, et al. Ethanolic extract of Alternanthera sessilis: a potential therapeutic agent for behavioral improvements in reserpine-induced parkinsonian rats. Int. J. Pharm. Sci. Drug Res., 16(2), 251–9 (2024) https://doi.org/10.25004/IJPSDR.2024.160215
Saewanee N, Praputpittaya T, Malaiwong N, Chalorak P, Meemon K. Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in Caenorhabditis elegans model of Parkinson’s disease. Neurosci. Res., 162, 13–21 (2021) https://doi.org/10.1016/j.neures.2019.12.017
Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson’s disease with the alpha-synuclein protein. Front. Pharmacol., 11, 356 (2020) https://doi.org/10.3389/fphar.2020.00356
Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing Res. Rev., 89, 101979 (2023) https://doi.org/10.1016/j.arr.2023.101979
Zemgulyte G, Umbrasas D, Cizas P, et al. Imeglimin is neuroprotective against ischemic brain injury in rats: a study evaluating neuroinflammation and mitochondrial functions. Mol. Neurobiol., 59(5), 2977–91 (2022) https://doi.org/10.1007/s12035-022-02765-y
Daroi PA, Dhage SN, Juvekar AR. p-Coumaric acid protects against D-galactose-induced neurotoxicity by attenuating neuroinflammation and apoptosis in mice brain. Metab. Brain Dis., 37(7), 2569–79 (2022) https://doi.org/10.1007/s11011-022-01007-3
Danışman B, Ercan Kelek S, Aslan M. Resveratrol in neurodegeneration, neurodegenerative diseases, and redox biology of mitochondria. Psychiatry Clin. Psychopharmacol., 33(2), 147–55 (2023) https://doi.org/10.5152/pcp.2023.23633
Islam MR, Rauf A, Akter S, et al. Neuroprotective potential of curcumin in neurodegenerative diseases: clinical insights into cellular and molecular signaling pathways. J. Biochem. Mol. Toxicol., 39, e70369 (2025) https://doi.org/10.1002/jbt.70369
Gadhave DG, Sugandhi VV, Jha SK, et al. Neurodegenerative disorders: mechanisms of degeneration and therapeutic approaches with clinical relevance. Biomed. Pharmacother., 162, 114671 (2023) https://doi.org/10.1016/j.biopha.2023.114671
Ono K, Tsuji M, Yamasaki TR, Pasinetti GM. Anti-aggregation effects of phenolic compounds on α-synuclein. Molecules, 25(10), 2444 (2020) https://doi.org/10.3390/molecules25102444
Li S, Wang Z, Liu G, Chen M. Neurodegenerative diseases and catechins: (−)-epigallocatechin-3-gallate as a modulator of chronic neuroinflammation and oxidative stress. Front. Nutr., 11, 1425839 (2024) https://doi.org/10.3389/fnut.2024.1425839
Supriya BK, Kumar NP, Gurung P, Bhujel B, Gupta D, Deekshitha A. Antiparkinsonian activity of hydroalcoholic extract of Operculina turpethum roots in reserpine-induced parkinsonism in Wistar rats. Indian J. Sci. Technol., 16(48), 4710–20 (2023) https://doi.org/10.17485/ijst/v16i48.3023
Leão AH, Sarmento-Silva AJ, Santos JR, Ribeiro AM, Silva RH. Molecular, neurochemical, and behavioral hallmarks of reserpine as a model for Parkinson's disease: new perspectives to a long-standing model. Brain Pathol., 25(4), 377–90 (2015) https://doi.org/10.1111/bpa.12253
Ahmed OG, Mahmoud M, Abdelhamid AA. Behavioral evaluation of rotenone model of Parkinson’s disease in male Wistar rats. Sohag Med. J., 24(2), 8–14 (2020) https://doi.org/10.21608/smj.2020.21596.1089
Nandagopal A, Khan MAA. Neuroprotective effect of polyherbal formulation in Parkinson’s animal model. Asian J. Pharm. Clin. Res., 13(3), 121–5 (2020) https://doi.org/10.22159/ajpcr.2020.v13i3.36549
Li Y, Yin Q, Wang B, Shen T, Luo W, Liu T. Preclinical reserpine models recapitulating motor and non motor features of Parkinson’s disease: roles of epigenetic upregulation of alpha synuclein and autophagy impairment. Front. Pharmacol., 13, 944376 (2022) https://doi.org/10.3389/fphar.2022.944376
Syed LAS, Koppaka RG, Prasad ES, et al. Ethanolic extract of Alternanthera sessile: a potential therapeutic agent for behavioral improvements in reserpine-induced parkinsonian rats. Int. J. Pharm. Sci. Drug Res., 16(2), 251–9 (2024) https://doi.org/10.25004/IJPSDR.2024.160215
Kamani B, Ganatra T. Unveiling the antiparkinsonian potential of Euphorbia tirucalli extract in a reserpine-induced rat model of parkinsonism: behavioral and neurochemical assessments. Egypt. J. Neurosurg., 40, 55 (2025) https://doi.org/10.1186/s41984-025-00387-9
Li Y, Yin Q, Li Q, et al. Botulinum neurotoxin A ameliorates depressive-like behavior in a reserpine-induced Parkinson’s disease mouse model by suppressing hippocampal microglial engulfment and neuroinflammation. Acta Pharmacol. Sin., 44, 1322–36 (2023) https://doi.org/10.1038/s41401-023-01058-x
Paulėkas E, Vanagas T, Lagunavičius S, Pajėdienė E, Petrikonis K, Rastenytė D. Navigating the neurobiology of Parkinson’s: the impact and potential of α-synuclein. Biomedicines, 12(9), 2121 (2024) https://doi.org/10.3390/biomedicines12092121
Lin M, Mackie PM, Shaerzadeh F, et al. In Parkinson’s patient-derived dopamine neurons, triplication of the α-synuclein locus induces distinctive firing patterns by impeding D2-receptor autoinhibition. Acta Neuropathol. Commun., 9, 107 (2021) https://doi.org/10.1186/s40478-021-01203-9
Guan L, Lin L, Ma C, Qiu L. Decoding crosstalk between neurotransmitters and α-synuclein in Parkinson’s disease: pathogenesis and therapeutic implications. Ther. Adv. Neurol. Disord., 18, 17562864251339895 (2025) https://doi.org/10.1177/17562864251339895
Cunha JM, Silva JVB, Zago D, et al. Short-term reserpine administration increases α synuclein immunolabeling in substantia nigra and striatum of rodents. Front. Neurosci., 16, 923957 (2022) https://doi.org/10.3389/fnins.2022.923957
Álvarez-Luquín DD, González-Fernández RR, Torres-Velasco ME, et al. Neurodegeneration models in Parkinson’s disease: cellular and molecular paths to neuron death. Behav. Brain Funct., 21(14), 1–20 (2025) https://doi.org/10.1186/s12993-025-00279-w
Goel R, Chaudhary R. Effect of daidzein on Parkinson’s disease induced by reserpine in rats. Braz. J. Pharm. Sci., 56, 183–8 (2021) https://doi.org/10.1590/s2175-97902019000318388
Khan MS, Nasiripour S, Bopassa JC, et al. Parkinson disease signaling pathways, molecular mechanisms, and potential therapeutic strategies: a comprehensive review. Int. J. Mol. Sci., 26(13), 6416 (2025) https://doi.org/10.3390/ijms26136416
Singh H, Khurana N, Bafna PA, Mazumder R, Sharma N. Neuroprotective effects of p-coumaric acid against chemical-induced dementia in mice. Pharmacol. Res. Mod. Chin. Med., 1(16), 100656 (2025) https://doi.org/10.1016/j.prmcm.2025.100656
Cao Y, Chen H, Tan Y, et al. Protection of p-coumaric acid against chronic stress-induced neurobehavioral deficits in mice via activating the PKA–CREB–BDNF pathway. Physiol. Behav., 273, 114415 (2024) https://doi.org/10.1016/j.physbeh.2023.114415
Published
How to Cite
Issue
Section
Copyright (c) 2025 Yogita R. Bagul, Laxman A. Kawale, Vandana S. Nade
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
